BioStock published an article on 4 February 2020 about Follicum, which can be read in full below. FOL-005, Follicum’s hair growth candidate, has received approval from German authorities to initiate a phase IIa study. Patient recruitment will commence shortly, and initial results are expected before the end of the year. The company’s aim is to then […]
BioStock published an article on 20 January 2020 about Follicum, which can be read in full below. Pharmaceutical drugs are often subdivided into two fractions: small molecules and large molecules (or biologics). However, a third category called peptides falls right in-between, thus generating an overlap of benefits from the other classes of molecules. Follicum’s two projects, […]
BioStock published an article on 18 December 2019 about Follicum, which can be read in full below. Both of Follicum’s projects, FOL-005 and the diabetes peptides, have reached important milestones this year. A topical formulation of the company’s hair loss treatment has successfully completed toxicology and safety profile clinical studies, and Follicum is all set […]
BioStock published an article on 17 December 2019 about Follicum, which can be read in full below. Yesterday, Follicum received a formal patent approval from the US Patent and Trademark Office protecting the hair project FOL-005 through 2032. In addition, the Lund-based company runs a diabetes project where previous preclinical studies have shown an ability […]
BioStock published an article on 6 December 2019 about Follicum, which can be read in full below. The competition within the therapeutic arena related to hair loss is limited as no new treatments have been registered during the last 25 years. However, the field got a big jolt last month as Irish big pharma giant […]
BioStock published an article on 14 November 2019 about Follicum, which can be read in full below. Biotech company Follicum will conduct its upcoming Phase II study in hair loss together with the German CRO proDERM. The Charité Universitätsmedizin Berlin had previously been confirmed as a partner for the study, which is expected to start […]
BioStock published an article on 21 October 2019 about Follicum, which can be read in full below. Today, news broke that Follicum had completed the supplementary toxicology studies that will form the basis for the upcoming phase II trial with their topical formulation of FOL-005. The study results were positive, safeguarding the company’s expectation to initiate […]
BioStock published an article on 30 September 2019 about Follicum, which can be read in full below. Follicum’s business strategy is to enter into a partnership, out license or sell their candidates following phase II trials at the latest. With proof-of-concept and top-line-data for FOL-005 firmly within reach during 2020, the company is getting closer […]
What is your background and what have you done before joining Follicum? I have been in the pharmaceutical industry for more than 30 years. After some years in ACO and Pharmacia I joined Recip in 1995 when it started its business. With the exception of one year at Meda in 2008, I have been with […]
This week the yearly event Nordic Life Science Days (NLSDays) took place in Malmö, Sweden. BioStock took the opportunity to talk to Jan Alenfall, the CEO of Follicum, about the status of the company’s projects – hair growth and diabetes. See the interveiw, in English, here. For further information, please contact: Jan Alenfall – CEO, […]